Akari Therapeutics Plc (AKTX): restructuring charge — Akari Therapeutics reduces workforce by 67% after suspending HSCT-TMA program

Akari Therapeutics Plc

Workforce reduction of ~67% implemented May 1, 2024; includes elimination of senior management positions.
Expected severance and related costs $3.1–3.2M, including ~$1.6M non-cash equity vesting; costs payable through Q4 2024.
Board member Rachelle Jacques resigned May 7, 2024; board reduced to five members with no disagreement reported.
Reduction is part of restructuring to cut HSCT-TMA operating costs and support long-term strategic plan.

item 2.05 item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Rachelle Jacques

Director

AKTX · Akari Therapeutics Plc

Effective: 2024-05-07
Filed: May 7, 2024, 7:59 PM ET

On May 7, 2024, Rachelle Jacques resigned from the Board of Directors (the “Board”), effective May 7, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Rachelle Jacques resigned as Director at Akari Therapeutics Plc.

Action: resigned
Role: Director

Exact text from the filing

On May 7, 2024, Rachelle Jacques resigned from the Board of Directors (the “Board”), effective May 7, 2024.

View on SEC.gov

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Akari Therapeutics Plc announced a restructuring with charges of approximately $3.1 million to $3.2 million (approximately 67% of its total workforce).

Type: restructuring
Charge: approximately $3.1 million to $3.2 million
Headcount: approximately 67% of its total workforce

Exact text from the filing

expects expenses related to the reduction-in-force, consisting primarily of cash severance and termination benefits and related costs, to be in the range of approximately $3.1 million to $3.2 million, which includes approximately $1.6 million of non-cash expenses related to vesting of equity awards. The Company expects these costs to be payable through the

View on SEC.gov

28 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Akari Therapeutics Plc filing history →

Source: SEC EDGAR

accession 0000950170-24-054726

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.